A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer

BACKGROUND. In the absence of a targeted oncogenic driver mutation or high programmed death‐ligand 1 expression, systemic therapy with platinum‐based doublet chemotherapy with or without bevacizumab has been the standard treatment in advanced or metastatic non‐small cell lung cancer (NSCLC). Metform...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrone, Kristen A., Zhou, Xian, Forde, Patrick M., Purtell, Michael, Brahmer, Julie R., Hann, Christine L., Kelly, Ronan J., Coleman, Barbara, Gabrielson, Edward, Rosner, Gary L., Ettinger, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058336/
https://www.ncbi.nlm.nih.gov/pubmed/29487223
http://dx.doi.org/10.1634/theoncologist.2017-0465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058336/
https://www.ncbi.nlm.nih.gov/pubmed/29487223
http://dx.doi.org/10.1634/theoncologist.2017-0465

Ejemplares similares